Board of Directors

 

John S. Yu, MD
CEO & Chairman

  • Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center.
  • Developed numerous immunotherapies and nanotechnologies from his NIH funded laboratory.
  • Developed 8 new investigational drugs with the FDA and has led numerous clinical trials.
  • Former officer of ImmunoCellular Therapeutics.
  • BAS from Stanford, MD from Harvard Medical School and MIT.
  • Immunology Fellowship at the Institute Pasteur, Paris, Neurosurgery Residency at Massachusetts General Hospital/Harvard.
 

Hyun W. Bae, MD
Independent Director

  • Professor of Surgery in Orthopaedic Surgery Cedars Sinai Medical Center, Director of Education and Fellowship program. Clinical partner of the basic science and translational Orthopaedic Stem Cell and Tissue Engineering Laboratory.
  • 20+ years experience in drug development, PI for 3-4 FDA-approved randomized clinical trials with over 30 clinical studies completed throughout his career.
  • Renowned Researcher (60+ published scientific papers, 5 review articles) and Inventor (30 patents).
  • Biomechanics degree from Columbia, MD cum laude from Yale, former NIH Howard Hughes Research Fellow Bethesda, MD.
  • Chief Medical Officer and Director of Prosidyan. Scientific Advisory Board Member of Mesoblast, Tissuegene, Spine Biopharma and Engage Surgical.
 

Rosemary Mazanet MD, PhD
Independent Director

  • 30+ year career as a celebrated Biotech investor, advisor, capital markets and C-suite executive at several biopharma companies, leading development programs ranging from IND submission through NDA approval and commercial launch.

  • Former Head of Clinical Research at Amgen, Inc. As one of the first US trained clinician scientists in her field, she led multiple successful product development initiatives (4 INDs and sBLAs, one BLA, CE mark and IDE) including FDA panel presentations.

  • Held subsequent executive positions at numerous NY-based firms including Argenis LP and Oracle Partners LP, one of the first health-care focused hedge funds.

  • Co-founded Apelles Investment Management, a healthcare focused financial services firm that specialized in cross-capital structure, credit and stressed/distress investing.

  • Chief Scientific Officer at Columbia Care, Trustee at the University of Pennsylvania Health System (her alma mater) and Chair, Executive Advisory Board for the Wharton Leonard Davis Institute.

  • Trained in Internal Medicine and Oncology at the Brigham and Women’s Hospital/Harvard Dana Farber Cancer Institute.

 

Michael Keyoung, MD, Ph.D
Independent Director

  • MD and Head of North America for CBC Group, a healthcare-dedicated private equity firm with over US$2 Billion AUM.
  • 20+ year career as a physician, biotech executive and institutional investor in US, Europe and Asia having advised Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial/partnership strategies.
  • Former CEO of Genexine (KOSDAQ: 095700 w/ $1 Billion market cap), led clinical development in Europe and Asia, raised $100 Million and created partnerships with Merck, Fosun Pharma, Tasly Pharma and Kalbe Pharma valued at over $250 Million.
  • Former President of Catalyst Biosciences, (NASDAQ: CBIO) a Hemophilia and Ophthalmology clinical stage company partnered with Pfizer, MedImmune and Isu Abxis.
  • MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, biomedical fellow at Rockefeller and MSKCC.
  • Board Chair of AffaMed Therapeutics and Director of Graybug Vision and InxMed.

John S. Yu, MD
CEO & Chairman

  • Professor and Clinical Chief of Neurosurgery, Director of the Brain Tumor Center at Cedars Sinai Medical Center.
  • Developed numerous immunotherapies and nanotechnologies from his NIH funded laboratory.
  • Developed 8 new investigational drugs with the FDA and has led numerous clinical trials.
  • Former officer of ImmunoCellular Therapeutics.
  • BAS from Stanford, MD from Harvard Medical School and MIT.
  • Immunology Fellowship at the Institute Pasteur, Paris, Neurosurgery Residency at Massachusetts General Hospital/Harvard.

Hyun W. Bae, MD
Independent Director

  • Professor of Surgery in Orthopaedic Surgery Cedars Sinai Medical Center, Director of Education and Fellowship program. Clinical partner of the basic science and translational Orthopaedic Stem Cell and Tissue Engineering Laboratory.
  • 20+ years experience in drug development, PI for 3-4 FDA-approved randomized clinical trials with over 30 clinical studies completed throughout his career.
  • Renowned Researcher (60+ published scientific papers, 5 review articles) and Inventor (30 patents).
  • Biomechanics degree from Columbia, MD cum laude from Yale, former NIH Howard Hughes Research Fellow Bethesda, MD.
  • Chief Medical Officer and Director of Prosidyan. Scientific Advisory Board Member of Mesoblast, Tissuegene, Spine Biopharma and Engage Surgical.

Rosemary Mazanet MD, PhD
Independent Director

  • 30+ year career as a celebrated Biotech investor, advisor, capital markets and C-suite executive at several biopharma companies, leading development programs ranging from IND submission through NDA approval and commercial launch.

  • Former Head of Clinical Research at Amgen, Inc. As one of the first US trained clinician scientists in her field, she led multiple successful product development initiatives (4 INDs and sBLAs, one BLA, CE mark and IDE) including FDA panel presentations.

  • Held subsequent executive positions at numerous NY-based firms including Argenis LP and Oracle Partners LP, one of the first health-care focused hedge funds.

  • Co-founded Apelles Investment Management, a healthcare focused financial services firm that specialized in cross-capital structure, credit and stressed/distress investing.

  • Chief Scientific Officer at Columbia Care, Trustee at the University of Pennsylvania Health System (her alma mater) and Chair, Executive Advisory Board for the Wharton Leonard Davis Institute.

  • Trained in Internal Medicine and Oncology at the Brigham and Women’s Hospital/Harvard Dana Farber Cancer Institute.

Michael Keyoung, MD, Ph.D
Independent Director

  • MD and Head of North America for CBC Group, a healthcare-dedicated private equity firm with over US$2 Billion AUM.
  • 20+ year career as a physician, biotech executive and institutional investor in US, Europe and Asia having advised Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial/partnership strategies.
  • Former CEO of Genexine (KOSDAQ: 095700 w/ $1 Billion market cap), led clinical development in Europe and Asia, raised $100 Million and created partnerships with Merck, Fosun Pharma, Tasly Pharma and Kalbe Pharma valued at over $250 Million.
  • Former President of Catalyst Biosciences, (NASDAQ: CBIO) a Hemophilia and Ophthalmology clinical stage company partnered with Pfizer, MedImmune and Isu Abxis.
  • MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, biomedical fellow at Rockefeller and MSKCC.
  • Board Chair of AffaMed Therapeutics and Director of Graybug Vision and InxMed.